FROM IDEAS TO INNOVATION

15–16 April 2026

30 Euston Square, London



PROSTATE CANCER UK

We can't wait to welcome you to FROM IDEAS TO INNOVATION!

Our inaugural event in 2024 was a huge success! Many of you told us about connections and collaborations sparked over those two days that are already driving progress for men with prostate cancer.

This year, I'm thrilled that we're able to showcase our Transformational Impact Awards for the first time: large-scale investments that span high-quality discovery science through to translational and clinical studies. We'll also hear about TRANSFORM, the biggest prostate cancer screening trial in 20 years, and explore the breadth of groundbreaking research happening through our Research Innovation Awards.

I'm delighted that each session will again feature a Patient Research Partner - men affected by prostate cancer, or a member of their family - whose invaluable insights guide the design, funding and delivery of all our work.

Prostate Cancer UK is proud to support future research leaders, and sessions at this year's event will be chaired by some of our brilliant Career Acceleration Fellows. With a record number of posters, there'll be no shortage of inspiring science to explore, and I'm looking forward to the discussion session as an opportunity for us all to come together and help shape a research community where everyone has the chance to thrive and to make an impact for men with prostate cancer.

From Ideas to Innovation has been designed by researchers, for researchers, so let's celebrate our outstanding research community - share, network and collaborate!

Dr Matthew Hobbs, Director of Research, Prostate Cancer UK

For the safety of all delegates, please do not bring nut-containing foods into the conference venue.

We're grateful to Artera for their generous sponsorship of From Ideas to Innovation.

Artera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalise cancer care. Artera's MMAI platform leverages a patient's digitised histopathology images along with the patient's clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomised trials, across different cancers, and is available in multiple versions across the globe.

Artera's flagship product, the ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions.

Meet Prostate Cancer UK's Research team

Dr Matthew Hobbs
Director of Research

Simon Grieveson
Assistant Director of Research

Dr Julia Ambler
Head of Research Funding

Dr Hayley Luxton
Head of Research Impact & Engagement

Dr Rachel Hallet
Diagnosis Research Lead

Wesley Gilchrist
Grant Manager

Krishna Kothandapani
Grant Manager

Amrit Mann
Grant Manager

Marie Girodengo
Senior Research Officer

Dr Ivana Steiner
Senior Research Officer

Ellie Davison
Research Impact & Engagement Manager

Dr Paidamoyo Katsande
Research Impact & Engagement Manager

Dr Sam Hodder
Senior Research Impact Officer

Dr Jonathan Scarfe
Senior Research Impact Officer

Career Acceleration Fellowships

Apply for up to £350K to support promising early career researchers to pursue their own independent research goals. Use the funds to establish collaborations, learn new skills & techniques, and support your development towards becoming an independent prostate cancer researcher.

OPEN NOW

Deadline 26 May 2026

Find out more

Scientific Organising Committee

A huge thank you to our Scientific Organising Committee, for your irreplaceable contributions towards this event:

Dr Victoria Dunne
Queen's University Belfast

Dr Greg Shaw
University College London

Dr Asma Ahmed
University of Glasgow

Dr Mick Brown
University of Manchester

Dr Susan Heavey
University College London

Dr Claire Fletcher
Imperial College London

> **From Ideas to Innovation will allow multidisciplinary networking within prostate cancer research, with an exciting, comprehensive programme.**

Dr Jennie Jeyapalan, University of Nottingham

Dr Jennie Jeyapalan
University of Nottingham

Dr Alan McWilliam
University of Manchester

Professor Paula Mendes
University of Birmingham

Dr Emma Scott Newcastle University

Professor Charlotte Bevan
Imperial College London

Dr Ning Wang
University of Leicester

Dr Jason Webber
Swansea University

From Ideas to Innovation will be a great forum to interact with other prostate cancer researchers and find out the latest research leads.

Professor David Elliott, Newcastle University

Professor David Elliott
Newcastle University

Wednesday 15 April

9:00–10:00	Registration and coffee.
10:00–10:15	Event opening.
10:15–11:15	Treatment Resistance, plus Research Snapshots.
11:15–11:45	Break.
11:45–12:45	Prostate Cancer Risk, plus Research Snapshots.
12:45–13:45	Lunch and posters.
13:45–14:25	TRANSFORM.
14:25–15:30	From Conversation to Commitment: Equity in Research Career Progression.
15:30–16:00	Break.
16:00–17:00	Imaging and Staging, plus Research Snapshots.
17:00–18:00	Drinks reception and posters.

Thursday 16 April

9:00–10:00	Breakfast and posters.
10:00–10:15	Prostate Cancer UK – Strategic Update.
10:15–11:15	Tumour Microenvironment, plus Research Snapshots.
11:15–11:45	Break.
11:45–12:45	Primary and Metastatic Cancer, plus Research Snapshots.
12:45–13:45	Lunch and posters.
13:45–14:15	Prostate Cancer UK – Funding and Support.
14:15–15:15	Smarter Treatment, plus Research Snapshots.
15:15–15:45	Break.
15:45–16:45	Advanced Prostate Cancer, plus Research Snapshots.
16:45–17:00	Closing remarks.

DAY 1: WEDNESDAY 15 APRIL 10AM–10:15AM

EVENT OPENING

CHAIR

Dr Matthew Hobbs, Director of Research, Prostate Cancer UK

Dr Matthew Hobbs is responsible for developing and overseeing our ambitious research strategy, making sure that we fund the research with the best chance of making a difference for men, and ensuring that our research supports, and is supported by, Prostate Cancer UK's wider programme.

DAY 1: WEDNESDAY 15 APRIL 10:15AM–11:15AM

TREATMENT RESISTANCE, PLUS RESEARCH SNAPSHOTS

CHAIR

Dr Jane Shortall, Prostate Cancer UK Career Acceleration Fellow, University of Manchester.

Risk stratification and follow-up for men receiving radiotherapy could be improved by advanced imaging biomarkers and data-driven methods. By integrating an individual's anatomy, biological make-up, and treatment response over time, the aim is to enable earlier response detection and move towards more personalised prostate cancer care for all men.

TRANSFORMATIONAL IMPACT AWARD

Targeting CXCR1 and CXCR2 blockade to maximise clearance of myeloid cells from advanced prostate cancer and reverse resistance to therapy.

Prostate cancer growth and survival are impacted by non-malignant cells, including white blood cells. Treatment strategies that remove white blood cells that fuel prostate cancer growth, and increase immune cells that kill tumours, are an urgent priority. Treatment strategies that can transform prostate cancer care are being pursued, to improve survival, quality of life, and possibly even cure rates. The ASPIRE early-phase clinical trial, made possible by a Transformational Impact Award, aims to increase understanding of such a strategy and how it impacts prostate cancer, testing whether a new tablet can improve hormone therapy outcomes for men with prostate cancer.

Professor Johann de Bono, Regius Professor of Cancer Research and Honorary Consultant in Medical Oncology, The Institute of Cancer Research, London & The Royal Marsden Hospital.

Dr Alec Paschalis, Group Leader, The Institute of Cancer Research, London & The Royal Marsden Hospital.

TRANSFORMATIONAL IMPACT AWARDS

Providing funding of up to £2m to collaborative teams to deliver clinical trials or programmes of research that will significantly transform our understanding of prostate cancer and how we diagnose and treat it.

Next round opens June 2026

Click here for more info

TRANSFORMATIONAL IMPACT AWARD

Continued...

Simon Aylett, Patient Research Partner.

Simon first collided with prostate cancer in 2011 at age 49. He had a radical prostatectomy in 2012, and in 2013 found the disease had metastasised to his lymph nodes. Simon received hormone therapy, radiotherapy, chemotherapy, and then enzalutamide. Each treatment worked for a while, until in 2017 he was told he had about one year of life left. In 2018, Simon cycled his ebike, towing a caravan, from Rye to Ortigia in southern Sicily, raising £45,000 for Prostate Cancer UK. By 2019 his PSA levels were doubling every three weeks, and he was not a well man. In January 2020 he enrolled in his first clinical trial under the auspice of Professor de Bono. The treatment worked so well, and the tumours shrank so colossally, that in 2021 Simon cycled 4,500 miles around the UK coastline towing his caravan, raising funds for The Royal Marsden's Drug Development Unit.

RESEARCH SNAPSHOTS:

Dr Pochuan Chiu, Research Associate,
Imperial College London.
Development of CAR-T therapy for prostate cancer.

Prostate tumors are immunologically cold, limiting the efficacy of current immunotherapies. STEAP-1 CAR-T cells were engineered to release a collagen-binding domain IL-12 (CBD-IL-12) upon antigen recognition, enabling enhanced localised immune activation while minimizing systemic exposure. Extending CBD-IL-12 armouring to CAF-targeted CAR-T cells may further help overcome stromal immunosuppression in prostate cancer.

RESEARCH SNAPSHOTS:

Continued...

Dr Caroline Dalgliesh, Research Associate, Newcastle University.

Harnessing epithelial RNA processing to understand aggressive prostate cancer and potential future therapy.

Elevated levels of ESRP1 and ESRP2 splicing regulators are associated with aggressive prostate cancer. To find out why some tumours have a more aggressive course, ESRP1 levels and target exons will be manipulated, with the aim of identifying specific gene networks associated with aggressive cancer as possible future therapeutic targets.

Dr Ralf Zwacka, Reader in Cancer and Stem Cell Biology, University of Essex.

MSC-mediated delivery of TRAIL for the treatment of prostate cancer.

MSC-delivered TRAIL variants targeting TRAIL-R2/DR5 demonstrated tumour growth retardation in PC3 and C4-2B xenografts without toxicity in murine models. Induced MSCs engineered to produce sTRAIL^{DR5} achieved comparable efficacy, confirming both platforms as safe, effective strategies for prostate cancer therapy and advancing preclinical development.

11:15AM-11:45AM BREAK

OPEN ACCESS REIMBURSEMENT SCHEME

We strongly recommend that the findings of the research we fund are made freely available to our supporters and the global research community. To maximise reach and impact, we'll reimburse the costs of open access publishing.

Find out more and how to apply

PROSTATE CANCER RISK PLUS RESEARCH SNAPSHOTS

CHAIR

Dr Koichi Sasaki, Prostate Cancer UK Career Acceleration Fellow, Imperial College London.

Immunotherapy is transforming cancer treatment, but current CAR-T therapies struggle to target tumours safely and work poorly in solid cancers like prostate cancer. STEAP1-targeted CAR-T cells and a collagen-binding IL-12 have been developed that boost immune attack inside tumours while limiting side effects, showing strong, long-lasting effects in mouse prostate cancer models.

TRANSFORMATIONAL IMPACT AWARD

Leveraging Pan Prostate Cancer Group (PPCG) resources for predicting prostate cancer outcome and to facilitate cancer prevention.

The PPCG Transformational Impact Award brings together a national consortium to define and translate the genomic, epigenomic and microenvironmental determinants of aggressive prostate cancer. Integrating germline, somatic, microbial and lifestyle data across richly phenotyped cohorts, the programme seeks to build biologically anchored risk prediction models and precision early detection tools. Within this, our Cambridge team leads the cell-free DNA arm, applying low-input methylation profiling to ctDNA for non-invasive detection and classification. These liquid-biopsy approaches aim to track tumour and immune-derived signals in plasma, forming the basis of future screening and treatment-monitoring strategies across high-risk and early-stage disease.

Professor Colin Cooper, Professor of Cancer Genetics, University of East Anglia.

Mr Harveer Dev, Academic Urologist and Group Leader, University of Cambridge Early Cancer Institute.

TRANSFORMATIONAL IMPACT AWARD

Continued...

Robin Porter, Patient Research Partner.

Robin is a retired 80-year-old, with a legal and academic background, who was diagnosed with low-risk, localised Prostate Cancer in 2006. He has been a volunteer with Prostate Cancer UK since 2008 and has served on various national research and funding committees as a patient representative, as well as in various prostate cancer awareness and media roles. He was on active surveillance from 2006 to 2019 and since then received HIFU treatments in 2020 and 2021, and radiotherapy in 2024. From 2006 to the present time, his prostate cancer has remained localised, and he is physically fit.

RESEARCH SNAPSHOTS

Professor Ananya Choudhury, Chair and Honorary Consultant in Clinical Oncology, University of Manchester

The twenty thousand men problem: decision-making in localised prostate cancer using genomic biomarkers.

Currently, it is unclear whether an individual man with prostate cancer will benefit more from radiotherapy or surgery. While radiotherapy cures most disease, radioresistance limits efficacy in some patients. A pre-treatment radiosensitivity biomarker would identify radioresponsive tumours for radiotherapy and radioresistant disease requiring surgery or intensified treatment in clinical practice.

Professor Aled Clayton, Director of Research for the School of Medicine, Cardiff University.

Probing tissue and blood for clues about cancer severity.

Spatial mapping of gene expression in prostate cancer identified molecular signatures linked to disease grade. RNA from serum vesicles correlated poorly with these signals, whereas whole serum RNA extracts yielded some markers that differentiated grade. These data support non-invasive serum diagnostic tests that may complement MRI and other modalities and inform biopsy decisions.

RESEARCH SNAPSHOTS:

Continued...



Dr Demi Pritchard, Research officer, Swansea University

Development of an assay using extracellular vesicle glycoproteins for early detection of aggressive prostate cancer.

Prostate cancer progression mechanisms remain unclear, though altered glycosylation is associated. An immunoaffinity platform has been developed for extracellular vesicle (EV) capture and glycan detection using lectins. EV glycoprofiles correlated with tumour aggressiveness in organoids and patient serum. EV-associated glycans represent promising non-invasive biomarkers for clinically significant prostate cancer detection.

Dr Srinivasa Rao, Senior Researcher in Cancer Genomics, University of Oxford.

Integration of spatial genomics with deep learning image analysis in prostate cancer.

Spatial-omics methods enable mapping of molecular data to histological images and could provide valuable insights into biological mechanisms driving cancer evolution and heterogeneity. However, molecular assays are expensive and not scalable to large sample numbers. Genomic information has been combined with image features to understand the relationship between genotype and phenotype.

LUNCH AND POSTERS

Researchers will be with their posters in the atrium during the second half of lunch (1:15pm-1:45pm) and during the drinks reception (5pm-6pm).

Please join us to network and celebrate the community's work. Poster details are available in the drinks reception section of the programme.



TRANSFORM

CHAIR

Dr Sarah Gosling, Prostate Cancer UK Career Acceleration Fellow, Keele University.

Deposits of calcium (calcifications) can capture information about the prostate tissue microenvironment when cancer is forming and progressing. Analysing the structure of prostate calcifications closely, looking for tiny changes, may help to find new markers for disease. This research could help doctors decide which men need treatment and which don't.

TRANSFORM

A randomised controlled trial to assess screening for prostate cancer compared to current standard of care.

Population-level prostate cancer screening is not currently recommended by any major healthcare system as the associated harms continue to outweigh the benefits. The UK National Screening Committee reaffirmed this position in its latest evidence review in 2025. TRANSFORM is a landmark national prostate cancer screening trial funded by Prostate Cancer UK aiming to deliver definitive evidence on optimal screening strategies by recruiting up to 300,000 men across the UK. Embedded within the trial, TRANSFORM Discovery will collect integrated biodigital data and tissue samples to generate a 'living' Bio-Digital Twin for each participant. This platform will enable real-time biomarker discovery and validation, accelerating progress toward safer, more effective approaches to early detection.

Professor Rakesh Heer, Chair of Urology, Imperial College London.

Professor Rhian Gabe, Professor of Biostatistics and Clinical Trials, Queen Mary University of London.

Dr Nikhil Mayor, Clinical Research Fellow, Imperial College London.

TRANSFORM

Continued...

Sue Duncombe, Patient Research Partner.

Sue's husband was diagnosed with prostate cancer at age 52. After he'd run out of licensed treatment options, he was fortunate to participate in the Phase 3 abiraterone trial. This drug both extended his life and improved his quality of life. This convinced Sue of the benefits of research. She is passionate about improving early diagnosis of cancer as well as improving treatment options for men with prostate cancer. She is an experienced PPI contributor, with roles on funding panels for Prostate Cancer UK and other charities. In addition, she's involved in a number of studies with a range of organisations.

RESEARCHER MENTORING SCHEME

Join our researcher mentoring scheme and strengthen the prostate cancer research community!

We pair researchers seeking career-focused support and development with experienced mentors outside their institution, offering valuable opportunities for growth and collaboration.

Find out more and register as a mentor, a mentee, or both!

FROM CONVERSATION TO COMMITMENT: EQUITY IN RESEARCH CAREER PROGRESSION

This session will explore barriers to thriving in the prostate cancer research community - featuring opening reflections from Black researchers - and ways the community can pledge to drive positive change.

CHAIR

Helen Eugene, Head of Equality, Diversity and Inclusion, Prostate Cancer UK.

Helen joined the charity in July 2023 and has since created their first EDI strategy and Positive Change Framework, which works to create a sense of belonging for colleagues, and underpin the Black Health Equity Strategy. Helen is a former civil servant, and has a bachelor's in Education Studies, and a master's in Social Justice end Education. Helen is currently completing a PhD at King's College London, looking at the lives and experiences of Black British men, particularly within the school to prison pipeline.

RESEARCHER REFLECTIONS

Dr Uzoamaka Okoli, Research Fellow, University College London.

Dr Uzoamaka Okoli is a Research Fellow on Dr Susan Heavey's Prostate Cancer UK-funded RADIO3D project, leading work packages on patient-derived explants, in vitro models, and spatial transcriptomics, and co-supervising junior researchers across projects in spatial omics, cancer disparities, and 3D modelling. She previously contributed to the Prostate Cancer UK Project SCREEN and is a Senior Lecturer at the University of Nigeria. Uzoamaka is committed to inclusive research culture. She joins this session to exchange ideas, reflect on career progression, and help shape a more supportive and equitable research environment.

RESEARCHER REFLECTIONS

Continued...

Manuella Siaka Monthe, PhD Student, Newcastle University.

Manuella is a Cancer Research UK Black Leaders in Cancer PhD student at Newcastle University, where her research focuses on how immunosuppressive sialoglycans on cancer-associated fibroblasts influence prostate tumour immunity and response to treatment. Manuella previously worked as a research assistant at the University of Oxford on a clinical trial for the early detection of liver cancer. As a Black woman in cancer research, she is passionate about equity in research career progression and is excited to share her experiences to help inspire and support others navigating similar paths.

Dr Emma Scott, Research Fellow, Newcastle University.

Emma is a group leader at Newcastle University investigating how glycans regulate the tumour immune microenvironment to drive immune suppression. Her group are focussed on understanding how sialylated glycans and Siglec immunoreceptors shape myeloid cell phenotype in the tumour immune microenvironment, and they are developing new glycan-based immunotherapies for prostate cancer. Emma is a previous Prostate Cancer UK Travelling Prize Fellow and she is currently supported by a Research Innovation Award. Emma is an equality, diversity and inclusion lead in the Newcastle University Biosciences Institute and is thrilled to be supporting Manuella Siaka Monthe, a PhD student in her lab, to share her experiences as a Black woman in science.

Dami Nwankpele, PhD Student, Imperial College London.

Dami is a first-year PhD student at Imperial College London. His Prostate Cancer Research-funded project focuses on researching the link between obesity and prostate cancer, as patients who are obese tend to experience a more aggressive type of cancer. The peri-prostatic adipose tissue may communicate with cancer cells, thereby worsening their aggressiveness, and the aim is to identify factors being communicated between these two sections and spatially visualise the effect of excess adipose tissue on prostate cancer. Hopefully, the results of this project will allow the identification of novel targets for treating patients with this cancer, improving treatment protocols and patient outcomes.

IMAGING AND STAGING, PLUS RESEARCH SNAPSHOTS

CHAIR

Dr Adriana Buskin, Prostate Cancer UK Career Acceleration Fellow, Newcastle University.

Adriana uses prostate organoids derived from induced pluripotent stem cells to investigate how primary cilia loss, cytoskeletal regulation, and castration resistant drivers shape tumour behaviour and therapy resistance. Her research aims to restore ciliogenesis to improve hormone therapy response and guide future translational strategies.

TRANSFORMATIONAL IMPACT AWARD

A randomised controlled trial to assess the clinical and cost-effectiveness of PSMA PET imaging to stage newly diagnosed high risk prostate cancer.

The trial will assess whether a single new scan called PSMA PET/CT should replace all standard staging scans for men with newly diagnosed high-risk prostate cancer (CT and bone scan). PSMA PET/CT uses a special tracer to detect cancer cells anywhere in the body and is highly accurate. However, it is not yet approved in NHS England because it's not known if treatment guided by this scan alone improves cancer outcomes compared to standard scans. In AVIDITY all patients will have all three scans and be randomly assigned to treatment guided by either standard imaging or PSMA PET/CT, with extra treatment such as cyberknife radiotherapy for all visible disease in the PSMA group. The study will report 4-year metastasis-free survival.

Professor Hashim Ahmed, Chair of Urology and Consultant Urological Surgeon, Imperial College London.

Dr Martin Connor, NIHR Clinical Lecturer in Urology, Imperial College London.

TRANSFORMATIONAL IMPACT AWARD

Continued...

Robert Oldroyd, BA MA FCLIP, Patient Research Partner.

Since successful treatment for prostate cancer in 2003, Robert was, until 2025, a member of the Prostate Cancer UK Research Advisory Group and its PPI group, the Research Strategy group, while supporting fundraising events including March for Men. Robert is a PPI representative on several trial management groups, including (among others) PROMIS, PACIFIC, TRANSFORM and AVIDITY. A member of the Nottingham Research Ethics Committee for nine years, he was a founder member of the Nottingham prostate cancer support group in 2004. Before retirement Robert was Director of Libraries at the University of Nottingham.

RESEARCH SNAPSHOTS

Professor Anne Kiltie, Friends of ANCHOR Clinical Chair in Oncology, University of Aberdeen.

DIETRICH Trial: Dietary fibre supplementation to reduce side effects of prostate radiotherapy.

With about half of men having radical radiotherapy for prostate cancer suffering gastrointestinal and urinary side effects which negatively impact quality of life, a randomised trial of the dietary fibre inulin versus placebo will be undertaken to test the hypothesis that men treated with inulin will have fewer gastrointestinal side effects.

SIGN UP TO OUR NEWSLETTER

Sign up to our monthly Research Newsletter for the latest updates on funding rounds, meetings and ways we can support you and your research!

Sign up today!



RESEARCH SNAPSHOTS

Continued...

Dr Debbie Moss, Postdoctoral Research Assistant, Johnston Cancer Research Centre, Queen's University Belfast.

ProFLASH - Exploring the role of photon FLASH radiotherapy in the management of prostate cancer.

Radiotherapy (RT) remains a central treatment for prostate cancer, but relapse and treatment-related toxicities are a major issue. FLASH-RT uses ultra-high dose rates that can reduce normal tissue toxicity whilst maintaining tumour control. The potential of FLASH-RT to spare nearby organs at risk, including the bladder, rectum, and bones, will be explored.

Professor Bill Nailon, Consultant Clinical Scientist, University of Edinburgh.

The PROSECCA study: a new approach for predicting radiotherapy outcomes using artificial intelligence and real-world electronic healthcare record data.

The PROSECCA project is using AI to analyse the electronic healthcare records (EHR) from 13,000+ prostate cancer patients who received radiotherapy. The relationship between information in a patient's EHR and how well they respond to radiotherapy is being investigated.

Dr Boris Tocco, Clinical Oncology Doctor and PhD student, King's College London.

Microbiota-based prediction of radiation enteropathy after radiotherapy for high-risk prostate cancer.

Pelvic radiotherapy for high-risk prostate cancer often causes radiation enteropathy. A predictive model will be developed and validated, integrating novel variables such as high-resolution gut microbiome taxonomy mapping and metabolomic outputs, alongside clinical and dosimetric parameters. This comprehensive approach will enable personalised radiotherapy approaches and reduce radiation enteropathy risk.

DRINKS RECEPTION AND POSTERS

Researchers will be with their posters in the atrium during the second half of lunch (1:15pm-1:45pm) and during the drinks reception (5pm-6pm). Please join us to network and celebrate the community's work.

Evening Social
If you'd like to carry on chatting, or unwind with fellow researchers - meet at 6pm in the atrium to head out together. Come for as long or as little as you like – everyone is very welcome.

WEDNESDAY POSTER PRESENTERS

Dr Omar H Ali, Academic Clinical Fellow, University of East Anglia.

Differential gene expression analysis of prostate cancer Gleason grade groups.

Dr Luisa Vanesa Biolatti, Research Fellow, University of Manchester.

A blood leucocyte-based radiotherapy transcriptomic prognostic signature in prostate cancer.

Dr Greg Brooke, Senior Lecturer, University of Essex.

Identifying men at high risk of developing prostate cancer.

Dr Kathy Chan, Group Leader, The Institute of Cancer Research, London.

Targeting PARP in prostate cancer: a radiotheranostic approach beyond PSMA.

WEDNESDAY POSTER PRESENTERS

Continued...

Dr Caroline Dalgliesh, Research Associate, Newcastle University.

Harnessing epithelial RNA processing to understand aggressive prostate cancer and potential future therapy.

Dr Laura Martínez Escardó, Postdoctoral Scientist and Honorary Research Fellow, CRUK Scotland Institute, University of Glasgow.

Reactivating mitochondrial cell death in prostate cancer: mechanisms and therapeutic opportunities.

Nuria Mascaro Fortuno, PhD Student, Imperial College London.

Understanding the abscopal effect in prostate cancer - primary to metastatic tumour crosstalk.

Dr Peter Godolphin, Senior Research Fellow, University College London.

Which patients with synchronous, metastatic hormone-sensitive prostate cancer benefit from prostate radiotherapy? STOPCAP meta-analysis of individual participant data.

Dr Sarah Gosling, Prostate Cancer UK Career Acceleration Fellow, Keele University.

Novel cancer biomarkers - investigating the role of microcalcifications in the prostate.

WEDNESDAY POSTER PRESENTERS

Continued...

Mr Samuel Hawkins, PhD Student, Cardiff University.

Targeting the PI3K pathway in prostate cancer.

Dr Rachel McCole, Postdoctoral Researcher, Queen's University Belfast.

Strategic chromatin remodelling by class I HDAC inhibition restores apoptotic competence in androgen-sensitive and resistant prostate cancer.

Professor Simon McDade, Professor of Functional Genomics, Queen's University Belfast.

Spatial longitudinal profiling in locally advanced prostate cancer: A Prospective ADT–EBRT cohort.

Professor Iain McEwan, Director of the Institute for Medical Sciences, University of Aberdeen.

AR-N-Terminal Domain inhibitors as a novel treatment modality for castrate resistant prostate cancer.

Hamida Mussa, Research Assistant, Imperial College London.

Development of a novel microRNA-based DNA-damaging therapeutic for the treatment of advanced prostate cancer.

Dr Uzoamaka Okoli, Research Fellow, University College London.

RADIO3D: modelling radioresistance and recurrence in patientderived organoids.

WEDNESDAY POSTER PRESENTERS

Continued...

Rodhan Patke, PhD student, University of Nottingham.

Epitranscriptomic signalling in advanced prostate cancer.

Dr Conrado Guerrero Quiles, Post-doctoral researcher, The University of Manchester.

Omics characterisation of recurrent tumours after radiotherapy in localised prostate cancer patients.

Dr Gareth Richards, Senior Research Fellow, University of Sheffield.

Discovery and development of first-in-class adrenomedullin-2 receptor antagonists for prostate cancer.

Dr Jane Shortall, Prostate Cancer UK Career Acceleration Fellow, University of Manchester.

Early consistent PSA monitoring after prostate radiotherapy predicts improved outcomes: a multicenter study.

Dr Joe Taylor, Prostate Cancer UK Career Acceleration Fellow, The Institute of Cancer Research, London.

The tumour suppressor PDCD4 regulates the androgen receptor signalling pathway and correlates with androgen receptor expression in advanced prostate cancer.

WEDNESDAY POSTER PRESENTERS

Continued...

Dr Nina Tunariu, Consultant in Radiology, The Royal Marsden Hospital & The Institute of Cancer Research, London.

The evolving role of Whole Body MRI in management of patients with prostate cancer.

Dr Daniel Turnham, Senior Research Fellow, The University of the West of England, Bristol.

Mechanistic insights into RAGE signalling in prostate cancer and the development of a RAGE-targeted antibody drug conjugate.

Dr Victoria Vickerstaff, Senior Lecturer in Medical Statistics, Queen Mary University College of London.

TRANSFORM trial of prostate cancer screening.

Dr Jason Webber, Associate Professor, Swansea University.

Development of an assay using extracellular vesicle glycoproteins for early detection of aggressive prostate cancer.

Jamie Wills, PhD student, Newcastle University.

Identifying ligands for the immune checkpoint Siglec-15 in prostate cancer.

RESEARCH INNOVATION AWARDS

Funding the boldest, brightest and most innovative projects in prostate cancer research. Covering fundamental and clinical research (and all stages in between), we're looking to support research that has real potential to significantly impact the way prostate cancer is diagnosed and treated.

NEXT ROUND OPENS JULY 2026

Find out more



BREAKFAST AND POSTERS

Researchers will be with their posters during the arrival breakfast (9am-10am) in the atrium and during the second half of lunch (1:15pm-1:45pm). Please join us to network and celebrate the community's work.

THURSDAY POSTER PRESENTERS

Dr Nicola Annels, Senior Research Fellow, University of Surrey.

Oncolytic viral therapy macrophage reprogramming is critical for establishing the immune infiltrate, which supported by IL-15, reverses immune checkpoint inhibitor unresponsiveness of prostate cancer.

Miss Aqua Asif, NIHR Academic Clinical Fellow in Urology, University College London.

PROACTive: building an innovation-ready prostate MRI service across the UK.

Denisa Bogdan, Clinical Studies Bioinformatician, The Institute of Cancer Research, London.

Plasma cell-free DNA nucleosome footprints indicate mechanisms of treatment sensitivity and resistance in mCRPC.

Dr Stefanie Bonfield, Postdoctoral Research Associate, Queen Mary University of London.

Insights from the PERSPECTIVES study - public perspectives of prostate cancer and PSA testing.

Poppy Brown, PhD Student, CRUK Scotland Institute, University of Glasgow.

Understanding the immunosuppressive and evasive mechanisms of prostate cancer.

THURSDAY POSTER PRESENTERS

Continued...

Dr Sarah Chambers, Senior Research Fellow, Queen's University Belfast.

Localised radiosensitisation through controlled release of lyophilised gold nanoparticles from biodegradable implants.

Professor Simon Crabb, Professor of Experimental Cancer Therapeutics, University of Southampton.

A Phase III open label randomised trial of androgen deprivation therapy plus androgen receptor pathway inhibition, with or without docetaxel intensification, in metastatic prostate cancer with a PSA ≥0.2 ng/ml at 6 months.

Dr Tabitha Cunliffe, Research Associate, Cardiff University.

BCL3: a promising therapeutic target to treat prostate cancer.

Dr Victoria Dunne, Lecturer in Molecular Radiotherapy, Queen's University Belfast.

Impact of ataxia-telangiectasia mutated (ATM) loss on radiobiological and immune response to radium-223 in prostate cancer in vitro models.

Dr Adam Duxfield, Research Associate, Newcastle University.

How cross-over between hormonal and oncogenic signalling regulates glyco-immune checkpoints in prostate cancer.

THURSDAY POSTER PRESENTERS

Continued...

Dr Miguel Reis Ferriera, Consultant Clinical Oncologist, King's College London & Guys and St Thomas NHS Foundation Trust.

Microbiota-based prediction of radiation enteropathy after radiotherapy for high-risk prostate cancer.

Dr Struan Gray, Clinical Research Fellow, The Christie Hospital.

The utility of skeletal muscle index as a prognostic and predictive biomarker in hormone sensitive prostate cancer: exploratory analysis of the STAMPEDE trial.

Jessica Hembrough, PhD student, European Cancer Stem Cell Research Institute, Cardiff University.

Targeting the Wnt ligand receptor complex as a novel therapeutic approach in prostate cancer.

Dr Ameera Jailani, Postdoctoral Research Associate, University of Sheffield.

Targeting adrenomedullin and its receptors in castrate-resistant prostate cancer.

Dr Yisheng Ji, PhD Student, Imperial College London.

Immune equilibrium as a switch of the abscopal effect during radiotherapy in metastatic prostate cancer.

THURSDAY POSTER PRESENTERS

Continued...

Dr Robert Kypta, Associate Professor in Cancer Cell Biology, Imperial College London.

Development of antibody-conjugated mesoporous silica nanotubes for targeted drug delivery to prostate cancer cells.

Dr Taha Lodhi, Clinical Research Training Fellow, University of Manchester.

Modelling radioresistance in prostate cancer: transcriptomic divergence in polyclonal DU145 cell populations.

Shauna McClelland, PhD Student, Queen's University Belfast.

Functional PTEN loss rewires AR-AKT crosstalk and alters therapeutic response in a novel AR-positive prostate cancer model.

Dr Alexander Ng, PhD Student, University College London.

Prostate MRI Analysis by Radiologists and Artificial Intelligence Disease Identification and Guided Management (PARADIGM): A trial in progress.

THURSDAY POSTER PRESENTERS

Continued...

Dr Ifeanyichukwu Nwanji, PhD Student, University of Nottingham.

Molecular determinants of aggressive prostate cancer in sub-Saharan African men.

Dr Simon Pacey, Academic Consultant in Medical Oncology, University of Cambridge.

Translational prostate cancer trials in Cambridge.

Dr Pasquale Rescigno, Clinical Senior Lecturer and Honorary Consultant, Newcastle University.

Abiraterone plus androgen deprivation therapy following radical treatment in high-risk localised prostate cancer: a real-world analysis of compliance and efficacy.

Aishwarya Shah, Medical Student, University College London.

Assessing the ethical implications of AI in prostate cancer care.

Rachel Thompson, PhD Student, University of Nottingham.

Selective inhibition of translation of prostate cancer.

THURSDAY POSTER PRESENTERS

Continued...

Dr Zhuolin Yang, Research Fellow, University of Edinburgh.

Establishing robust real-world side effect endpoints for prostate radiotherapy: national-level validation from the PROSECCA study.

> **From Ideas to Innovation will be a way to connect with peers, stay informed about prostate cancer research, and meet future collaborators.**
>
> Professor Paula Mendes, University of Birmingham

DISSEMINATING YOUR RESEARCH

Follow us on **@ProstateUKProfs** to be amongst the first to know about a recently published article.

As part of our weekly coffee club we highlight recently published papers, encourage you to grab a coffee (or your favourite beverage) and click on the link to read the paper.

Stay in the loop, share your thoughts, and be part of the conversation!

BlueSky X

PROFESSIONAL SUPPORT

RESEARCH STRATEGY

Dr Matthew Hobbs, Director of Research, Prostate Cancer UK.

Dr Matthew Hobbs will provide an update on ongoing work to develop Prostate Cancer UK's new 10-year research strategy.

TUMOUR MICROENVIRONMENT, PLUS RESEARCH SNAPSHOTS

CHAIR

Dr Rayzel Fernandes, Prostate Cancer UK Career Acceleration Fellow, Imperial College London.

Understanding how long non-coding RNAs (lncRNAs) drive therapy resistance in prostate cancer involves using computational analyses and genome-wide CRISPR screening to identify candidate lncRNAs. Therapy-sensitive and -resistant cell lines and organoid models are used to determine their mechanisms of action, with the ultimate aim of finding lncRNA associated pathways with therapeutic potential and prognostic utility.

TRANSFORMATIONAL IMPACT AWARD

Investigating the tumour microenvironment of high-risk localised prostate cancer to identify actionable pathways involved in cancer.

Patients with high-risk localised prostate cancer are at risk of residual or recurrent disease despite radical treatment and ultimately developing regional and distant metastasis. Dynamic interactions between cancer cells and multiple neighbouring cell types within the tumour microenvironment control the likelihood of cancer spread, including nodal metastasis in the draining pelvic lymph nodes. Well-curated clinical patient cohorts and complementary bespoke preclinical prostate cancer models are being used to study the prostate tumours and their draining lymph nodes as an ecosystem for cancer metastasis. Integrating machine learning based methodologies will hopefully reveal new targets for therapy.



Dr Ed Roberts, Group Leader, CRUK Scotland Institute, University of Glasgow.

TRANSFORMATIONAL IMPACT AWARD

Continued...

Vincent McGovern, Patient Research Partner.

Vincent McGovern is a 66-year-old retired criminal defence lawyer. Vincent is married with 3 adult sons, two of whom now run his former law practice, and he is a current legal member of the Scottish Solicitors Disciplinary Tribunal. Shortly after retiral, Vincent was diagnosed with prostate cancer. He had no symptoms prior to this diagnosis. Following excellent medical care culminating in a radical robotic prostatectomy, he was fortunate to receive a curative outcome with minimum side effects and remains in good health.

RESEARCH SNAPSHOTS

Dr Susan Heavey, Associate Professor, University College London.

Radio3D: Investigating radioresistant prostate cancer pre/post radiotherapy in 3D.

An update on Radio3D will be provided, outlining its purpose and current progress in modelling radiorecurrent and radioresistant prostate cancer. Advances integrating explant and organoid culture data will be highlighted, and key clinical cohort features summarised, emphasising Radio3D's potential to dissect resistance mechanisms and inform future therapeutic strategies.

STARTER GRANTS FOR CLINICAL LECTURERS

We are partnering with the Academy of Medical Sciences on their Starter Grants scheme to support research-active clinical lecturers. The grants provide funding for consumables as well as access to extra support through the academy.

Next round opens in July 2026

Find out more

RESEARCH SNAPSHOTS

Continued...

Dr Damien Leach, Research Fellow,
Imperial College London.

Understanding and targeting the influence of fibroblast and extracellular matrix on cancer progression.

How cancer associated fibroblasts become activated, how they change, and how these changes influence prostate cancer progression is being investigated. Specifically, patient tissue and 3D-in-vitro models are used to study how fibroblasts, and the protein/matrisome they produce, can be used prognostically and be manipulated to improve patient outcomes.

Dr Helen Pearson, Senior Lecturer and CRUK Fellow,
Cardiff University.

Preclinical evaluation of promising therapeutic strategies for prostate cancer.

AKT, BCL3 and CD200 small molecule inhibitors are being explored to understand prostate cancer treatment resistance. In vivo and ex vivo models are used to investigate molecular mechanisms and preclinically test innovative therapies aimed at improving patient outcomes.

Dr Nina Tunariu, Consultant in Radiology,
The Royal Marsden Hospital & The Institute of Cancer Research, London.

The evolving role of Whole Body MRI (WBMRI) in the management of patients with prostate cancer.

The role of WBMRI in the management of prostate cancer will be discussed, concentrating on treatment monitoring, timely detection of complications and its complementarity with PSMA PET CT. WBMRI offers a more accurate assessment of disease than standard CT and bone scan and thus has the potential to improve patient outcomes.

MRC CLINICAL RESEARCH TRAINING FELLOWSHIPS



These grants, jointly funded with the Medical Research Council, support healthcare professionals to do a PhD or reacquire research skills. Funds can cover salary, tuition fees and research costs of up to £25k, for three years.

Next round opens June 2026

Find out more

PRIMARY AND METASTATIC CANCER, PLUS RESEARCH SNAPSHOTS

CHAIR

Dr Corinne Woodcock, Prostate Cancer UK Career Acceleration Fellow, University of Nottingham.

N6-methyladenosine (m6A) is the most common epitranscriptomic mRNA modification and regulates gene expression, splicing, and translation. RNA methylation inhibitors are in Phase I clinical trials. Targeting m6A may be a novel approach to influence key oncogene and tumour suppressor pathways in prostate cancer.

TRANSFORMATIONAL IMPACT AWARD

Understanding the abscopal effect in prostate cancer – primary and metastatic tumour crosstalk.

Systemic investigation of the 'abscopal effect' – whereby treatment of the primary tumour can offer therapeutic benefit in disseminated disease – may provide new perspectives and treatment options for lethal, metastatic prostate cancer. It is hypothesised that therapy response and outcome is significantly determined by bidirectional crosstalk between the primary tumour and metastatic niche via circulating factors. Working with unique samples from IP2-ATLANTA (men with metastatic disease allocated to standard systemic therapy ± radical or focal therapy to the primary) and using pre-/post-treatment tissue/biofluids to study 'omic changes that accompany transitions, network nodal points that govern therapy responses will be defined.

Professor Charlotte Bevan,
Professor of Cancer Biology,
Imperial College London.

Nuria Mascaro Fortuno,
PhD Student,
Imperial College London.

Derek Price, Patient Research Partner.

Derek graduated in bacteriology and was awarded a master's for his dissertation on cancer and viruses, eventually teaching biology and chemistry in a school. His father died from oligometastatic prostate cancer, and Derek was diagnosed with the disease some years later and had a prostatectomy. After his surgery Derek began to volunteer for Prostate Cancer UK, giving talks and running information stands, and he was a patient representative on Prostate Cancer UK research committees for over ten years. Derek has reviewed research proposals for NIHR, is a member of NPCA, and is a member of the Clinical Research Strategy Group (formerly NCRI prostate group). Derek is currently a PPI representative on seven clinical trials.

RESEARCH SNAPSHOTS

Dr Eleanor Bellows, Postdoctoral Research Fellow, University of Nottingham.

Epitranscriptomic mechanisms in treatment resistant prostate cancer.



m6A RNA methylation is highly conserved and has been implicated in prostate cancer. The m6A demethylase FTO has higher cytoplasmic expression in advanced prostate cancer compared to non-malignant tissue samples. The epitranscriptome in FTO knock-out cell lines has been mapped, identifying altered m6A in key genes associated with castrate resistance pathways.

Dr Marco Bezzi, Tumour Functional Heterogeneity Group Lead, The Institute of Cancer Research, London.

From reconstruction to resolution: platform approaches to engineer the prostate cancer phenoscape and map its evolution.

Prostate cancer evolves through diverse phenotypic subtypes and lineage dynamics that are difficult to model. A scalable organoid–allograft platform capturing major disease states, and a universal multimodal barcoding system, has been developed. Together, they reconstruct tumour heterogeneity, resolve clonal behaviour, and expose therapeutic vulnerabilities in advanced prostate cancer.

Jess (Ziqian) Peng, PhD Student, Newcastle University.

Developing new glycan-targeting drugs to personalise prostate cancer treatment.



GALNT7 makes glycans on the surface of prostate cancer cells and can help tumours grow, spread, and escape the immune system. The aim is to understand why GALNT7 is so important in prostate cancer, and to develop new drugs targeting GALNT7 (and/or its glycans) as new therapies for advanced disease.

RESEARCH SNAPSHOTS

Continued...

Dr Gareth Richards, Senior Research Fellow, University of Sheffield

Targeting adrenomedullin-2 receptors (AM2R) to overcome hormone therapy resistance in prostate cancer.

Analysing patient blood samples revealed that adrenomedullin levels increase 27% following hormone therapy, activating survival pathways contributing to treatment resistance. Unique, first-in-class AM2R antagonists restore drug sensitivity in resistant tumour models—achieving 85% versus 32% growth inhibition with standard treatment. The aim now is to develop oral formulations for patients.

12:45PM - 1:45PM LUNCH

MAKING PROGRESS

Making Progress will be back 21 April 2027!

Making Progress is a meeting dedicated to the development of early career researchers working in prostate cancer research.

Find out more about making progress



FUNDING AND SUPPORT FOR RESEARCH

Simon Grieveson and Dr Hayley Luxton will highlight ways in which Prostate Cancer UK can support you and your research, from making introductions, our open access reimbursement scheme and helping to disseminate your research.

Simon Grieveson, Assistant Director of Research, Prostate Cancer UK.

Simon Grieveson implements Prostate Cancer UK's research strategy into business delivery plans, explores new opportunities to fund vital research and supports the prostate cancer research community, to ultimately benefit those affected by prostate cancer.

Dr Hayley Luxton, Head of Research Impact & Engagement, Prostate Cancer UK.

Dr Hayley Luxton leads the team that uncovers and communicates the impact of Prostate Cancer UK's research, while supporting the wider research community to accelerate lifesaving progress for men.

SMARTER TREATMENT, PLUS RESEARCH SNAPSHOTS

CHAIR

Dr Ahmet Hazini, Prostate Cancer UK Career Acceleration Fellow, University of Oxford.

Macrophages could be utilised as a cellular immunotherapy for prostate cancer, with particular emphasis on their role in tumour antigen cross-presentation and the induction of prolonged adaptive immune responses. This approach aims to provide an effective treatment option for prostate cancer patients at every stage of the disease.

TRANSFORMATIONAL IMPACT AWARD

STOPCAP 2 - Identifying which therapies are best for people with metastatic hormone-sensitive prostate cancer, and understanding barriers and facilitators to their uptake.

A key aim of the STOPCAP collaboration is to provide reliable results about which treatments are most effective for people with metastatic hormone-sensitive prostate cancer (mHSPC). However, if these results don't change clinical policy or practice, not all patients will benefit. What stops or encourages the use of particular findings or treatments is being explored with patients, clinicians, guideline developers and policymakers. A better understanding of the factors influencing their treatment choices and recommendations will help improve the communication and dissemination of results, to ensure wider access to the best treatments and improved outcomes for more people with mHSPC.

Professor Jayne Tierney, Professor of Evidence Synthesis, MRC Clinical Trials Unit at University College London.

Dr Hannah Rush, Medical Oncology Consultant, MRC Clinical Trials Unit at University College London & Guy's and St Thomas's NHS Foundation Trust.

Dr Annabelle South, Principal Research Fellow: Research Impact and Communication, MRC Clinical Trials Unit at University College London.

TRANSFORMATIONAL IMPACT AWARD

Continued...

Dr David Matheson, Patient Research Partner and Reader in Education for Health, School of Nursing and Midwifery, University of Wolverhampton.

David has been involved with Prostate Cancer UK since 2013 when he had just completed his first treatments for prostate cancer. He first trained as a speaker to give awareness talks for the charity and later completed media training, serving for several years as a patient representative on the Support and Influencing Committee. In 2013, he joined the Trial Management Group of STAMPEDE as a patient representative and from this he became involved in STOPCAP. He is Reader in Education for Health at the University of Wolverhampton where he researches wellness and lived experience in the context of prostate cancer.

RESEARCH SNAPSHOTS

Mr Cameron Alexander, Clinical PhD Fellow and Specialty Trainee in Urology, University of Manchester.

Understanding the relationship between systemic host features and metformin response in the STAMPEDE metformin trial.

The STAMPEDE metformin trial reported that the addition of metformin to standard-of-care therapy led to a 10-month overall survival improvement amongst patients with high-volume mHSPC (HR 0.79; 95% CI 0.66-0.93; p=0.0059), with no benefit observed in low-volume disease. The metabolic sub-study has facilitated the prospective collection of baseline and follow-up serum/plasma samples in this trial population to understand the relationship between systemic host features and metformin response.

Dr Kelly Coffey, Lecturer in Prostate Cancer, Newcastle University.

Understanding therapeutic target enzymatic activity, particularly kinases, guides effective treatment.

Multiplexed antibody cocktails assessed multiple kinase activities and their responses to inhibitors in ex vivo prostate tissue. Marked patient heterogeneity complicated interpretation, underscoring the need for precision strategies to optimise therapeutic benefit across diverse clinical cases and experimental models studied.

RESEARCH SNAPSHOTS

Continued...

Dr Chun-Fui Lai, Research Associate, Imperial College London.



Developing the use of CDK7 inhibitors for the treatment of prostate cancer.

CDK7 regulates cell cycle progression and transcription and has emerged as a promising cancer target. Our work focuses on identifying biomarkers of response and resistance upon CDK7 inhibition. These insights will guide the development of therapeutic strategies and support the clinical implementation of CDK7-targeted therapies for prostate cancer patients.

Dr Melissa LaBonte Wilson, Senior Lecturer in Molecular Oncology, Queen's University Belfast.

Targeting chromatin and epigenetic vulnerabilities in advanced prostate cancer.

How chromatin structure and epigenetic dysregulation shape therapy resistance in advanced prostate cancer is being defined. Integration of mechanistic models, chromatin imaging, and tumour profiling uncovers druggable vulnerabilities to guide the rational development of next-generation therapeutic combinations.

3:15-3:45PM BREAK

ADVANCED PROSTATE CANCER, PLUS RESEARCH SNAPSHOTS

CHAIR

Dr Emma Lishman-Walker, Prostate Cancer UK Career Acceleration Fellow, Newcastle University.

Emma investigates cell signalling in prostate cancer to identify biomarkers for personalised treatments using liquid biopsy approaches.

TRANSFORMATIONAL IMPACT AWARD

STAMPEDE Life: Temporal-spatial resolution of prostate cancer evolution to a lethal hormone and radioligand therapy resistant phenotype in metastatic patients randomised in the STAMPEDE2 trial.

Treatment intensification at diagnosis of metastatic prostate cancer improves survival, but 20-40% of patients still progress rapidly to castration resistant disease. Since September 2024, the STAMPEDE2 177Lu-PSMA trial has randomised newly diagnosed polymetastatic prostate cancer patients to receive radioligand therapy (RLT) in addition to standard-of-care (SOC) versus SOC alone (ADT+ARPI+/- docetaxel). STAMPEDELife incorporates prospective collection of blood for liquid biopsy studies, clinical outcomes and imaging after progression in STAMPEDE2, with co-recruitment of a subset of patients to the PEACE study for post-mortem harvesting of tumours followed by multi-omic characterisation. The aim is to define the mechanisms underlying evolution to a hormone and RLT resistant phenotype in polymetastatic prostate cancer.

Prof Gerhardt Attard, Director, University College London Cancer Institute.

Dr Ashwin Sachdeva, Clinical Senior Lecturer, University of Manchester.

Dr Emily Grist, Medical Oncologist, University College London.

TRANSFORMATIONAL IMPACT AWARD

Continued...

Dr Patrick Williams, Patient Research Partner.

Dr Patrick Williams was raised in Cardiff and Trinidad and Tobago. He performed globally as a dancer, including in Michael Jackson's Thriller video and tours with Janet Jackson and Grace Jones. Returning to the UK, Patrick earned a PhD in Dance, and focused on lecturing and choreography, working with Take That, Rhianna, and supporting Black British Ballet. Diagnosed with stage 4 prostate cancer in 2020, Patrick is dedicated to raising awareness, visiting many organisations and businesses. He is the face of Prostate Cancer UK's 'the good cancer' campaign and serves as a PPI representative, considering research proposals as part of the charity's scientific committees.

RESEARCH SNAPSHOTS

Dr Nicola Annels, Senior Research Fellow, University of Surrey.

Oncolytic viral therapy macrophage reprogramming is critical for establishing the immune infiltrate which, supported by IL-15, reverses immune checkpoint inhibitor unresponsiveness of prostate cancer.

The role that innate immunity plays in determining the responsiveness of prostate tumours to immune checkpoint inhibition following oncolytic virotherapy with Il-15 has been explored. Reprogrammed M1-like macrophages were key players in the recruitment of other immune effectors which, supported by IL-15, resulted in the success of immunotherapy.

Professor Francesco Crea, Professor of Cancer Pharmacology, Open University.

Precision epigenetics for neuroendocrine prostate cancer.

Precision epigenetic therapies for incurable neuroendocrine prostate cancer (NEPC) are being developed, including selective pharmacological inhibitors and biomarkers for patient stratification. An epigenetic inhibitor has been identified that's more effective than chemotherapy in NEPC models. Mechanistically, this inhibitor modulates apoptosis and antigen-presentation, pointing to potential synergy with available treatments.

RESEARCH SNAPSHOTS

Continued...



Dr James Hindley, Lecturer in the Physical Science of Life, King's College London.

Tumour-remodelling synthetic cells for cancer drug delivery.

Effective, well-tolerated treatments for therapy-resistant prostate cancer is a major clinical need. The mechanical properties of prostate tumours represent a major barrier to drug penetration. Microenvironment-remodelling drugs are being delivered to prostate cancers using tumour-sensing synthetic cell nanomedicines to reduce tumour stiffness, improve drug penetration, and ultimately improve treatment outcome.

Professor Ian Mills, John Black Professor of Prostate Cancer, University of Oxford.

Targeting transcription elongation to modify the prostate cancer tumor immune micro-environment.

There is a pressing need to improve the body's immune surveillance of the prostate to better detect and respond to cancer during its development and progression.
This presentation will describe a project to change the immunogenicity of prostate cancer cells using compounds targeting cyclin-dependent kinase 9 (CDK9) and touch on other strategies to change immune surveillance.

CLOSING REMARKS

Laura Kerby, CEO, Prostate Cancer UK.

Laura Kerby joined Prostate Cancer UK in February 2022 after previously serving as the Chief Executive of Myeloma UK and Penny Brohn UK. She's worked in health and wellbeing for two decades, holding various senior leadership positions and was an Executive Board member at Nuffield Health. She was motivated to join the charity by her own father's experience of prostate cancer, and is determined to ensure that, in future, lives are neither shortened nor limited by the disease.

AREAS OF KNOWLEDGE WITHIN OUR FUNDED RESEARCHERS

Based on information submitted as part of the registration form we've listed areas of knowledge among our funded researchers on the following pages. We encourage you to use this as a tool to find and reach out to new potential collaborators!

Name	Institution	Areas of Knowledge		
Professor Hashim Ahmed	Imperial College London	Prostate trials	Diagnosis	Therapy
Dr Asma Ahmed	University of Glasgow / CRUK Scotland Institute	Cell death	Tumour immunology	Mouse models
Mr Cameron Alexander	The Christie Hospital / University of Manchester	Clinical trials	Cancer metabolics	
Dr Omar Ali	University of East Anglia	Bioinformatics	Clinical research	Cancer genome sequencing
Dr Sadaf Ambreen	Queen Mary University of London	Bioinformatics	Molecular biology	Genomics
Dr Thineskrishna Anbarasan	University of Oxford	Artificial Intelligence	Prostate MRI	Spatial prostate biology
Dr Nicola Annels	University of Surrey	Spatial biology	Immune tumour microenvironment	Immunotherapy
Dr Michela Antonelli	King's College London	MRI for prostate cancer	Artificial Intelligence	Active Surveillance
Dr Aqua Asif	University College London	Clinical trials	MRI	Trial dissemination and communication
Professor Gerhardt Attard	University College London	Clinical trial management	Biomarkers	Molecular analysis
Dr Rachel Barker	University of Bristol	Translational research	Early detection	Circulating biomarkers
Dr Akang Bassey	Queen Mary University of London	Molecular biology	Cell biology	Collaboration
Ms Anjali Behal	Cancer Research UK	Early detection	Cancer screening	Innovation pipeline and ecosystem
Dr Eleanor Bellows	University of Nottingham	Epitranscriptomics	RNA-seq	Molecular biology
Ms Kate Bennett	Barts Clinical Trials Unit	Clinical trial design and endpoints	Data capture / Imaging data	Statistical challenges in trials and studies
Professor Charlotte Bevan	Imperial College London	Androgen signalling	Hormonal therapy	Non-coding RNA
Dr Marco Bezzi	The Institute of Cancer Research, London	Mouse models	Cancer evolution	Mass cytometry
Dr Matthew Blakeley	Imperial College London	Tumour microenvironment	Extracellular Matrix	Cancer Associated Fibroblasts

*We have done our best to provide accurate informationour sincerest apologies if anything is incorrect.

Ms Libby Blencoe	Newcastle University	Cancer	Pharmacology	Cell signalling
Professor Karen Blyth	CRUK Scotland Institute	Preclinical mouse models	Cell death	Therapies
Dr Oleg Blyuss	Queen Mary University of London	Medical statistics	Artificial Intelligence	Predictive Modelling
Miss Stefanie Bonfield	Queen Mary University of London	Behavioural science	Public and patient involvement	Socioeconomic deprivation
Professor Johann de Bono	The Institute of Cancer Research, London	Development of new treatments	Translational research	Circulating Biomarkers
Dr Baptiste Brauge	CRUK Scotland Institute	Cancer immunology		
Professor Daniel Brewer	University of East Anglia	Omics	Bioinformatics	Biomarkers
Professor Rob Bristow	University of Manchester	Prostate cancer	Translational oncogenomics	Hypoxia
Dr Greg Brooke	University of Essex	Androgen receptor	Racial disparities	Early diagnostics
Dr Mick Brown	University of Manchester	Mechanism of bone metastasis	Imaging	
Miss Poppy Brown	University of Glasgow / CRUK Scotland Institute	Molecular biology	Immunology	Mouse models
Professor Richard Bryant	University of Oxford	Clinical trials	Basic and translational science research	Preclinical research
Ms Sarah Burdett	MRC Clinical Trials Unit at UCL	Meta-analysis	Metastasis	Data collection
Ms Edwina Burke	Barts Cancer Institute, Queen Mary University of London	Immunofluorescence	Circulating tumour cells	Circulating biomarkers
Dr Adriana Buskin	Newcastle University	3D models	Single-cell RNA profiling	Treatment resistance mechanisms
Professor Karl Butterworth	Queen's University Belfast	Radiotherapy	Radiation biology	Toxicity models
Dr Adnan Chakra	Imperial College London	Microfluidics	Molecular biology	Synthetic cells
Dr Sarah Chambers	Queen's University Belfast	Gold nanoparticles	Radiation enhancement	Cellular biology

Dr Kathy Chan	The Institute of Cancer Research, London	Targeted-radiotheranostics	Targeted therapy for prostate cancer	
Dr Anjali Chander	King's College London	Microbiome	Tumour microenvironment	Tumour biology
Dr Pochuan Chiu	Imperial College London	CAR-T therapy	Cytokines	Tumour targeting
Professor Ananya Choudhury	University of Manchester	Biomarkers	Radiotherapy	Radioresistance
Professor Aled Clayton	Cardiff University	Spatial transcriptomics	Extracellular vesicles	Diagnostics
Dr Kelly Coffey	Newcastle University	Cell signalling	Ex vivo tissue slice	Kinase
Mr Martin Connor	Imperial College London	PSMA PET CT	Robotic radical prostatectomy	
Professor Colin Cooper	University of East Anglia	Whole genome sequence data	Microbiome	Biomarkers
Professor Simon Crabb	University of Southampton	Advanced prostate cancer	Clinical trials management	Biomarker development
Professor Francesco Crea	The Open University	Neuroendocrine prostate cancer	Epigenetics	Pharmacology
Mrs Gemma Cullen	Addenbrooke's Hospital	Clinical trial approaching, supporting and scheduling		
Dr Tabitha Cunliffe	Cardiff University	Metastasis	Mouse models	Molecular biology
Dr Caroline Dalgliesh	Newcastle University	Alternative splicing	Gene expression	RNA
Dr Harveer Dev	University of Cambridge	DNA repair	DNA methylation	Surgery
Ms Jade Dorrian	Queen's University Belfast	Periprostatic adipose tissue (PPAT)	Aggressive prostate cancer	Bioinformatics
Dr Dimitrios Doultsinos	University of Oxford	Lineage plasticity and acquired treatment resistance	Proteostasis, cellular homeostasis and the unfolded protein response	ECR funding
Ms Kate Duffy	University College Dublin	Extracellular vesicles	Patient derived explants	Science communication

Dr Victoria Dunne	Queen's University Belfast	Radiotherapy	Radionuclides	Molecular radiotherapy
Dr Adam Duxfield	Newcastle University	Immunology	Glycoimmunology	Flow cytometry
Dr Mark Eccleston	ValiRx	Therapeutic development	Cell model development	NAMS
Dr Giselle Edge	University of Manchester	Molecular biology	Cell culture	Gene editing
Professor David Elliott	Newcastle University	RNA	Gene expression	Splicing
Dr Laura Martinez Escardo	CRUK Scotland Institute	Cell death	BCL-2 family	Mitochondria
Mr Lucas Farndale	University of Glasgow / CRUK Scotland Institute	Cancer imaging	Machine learning / AI	Immunology
Dr Laura Feeney	Queen's University Belfast / Northern Ireland Cancer Centre	Cell culture	Histology	Molecular biology
Ms Yahui Feng	University of Leicester	Bone metastasis	Metabolism	Molecular biology
Dr Rayzel Fernandes	Imperial College London	CRISPR screening	Transcriptomics	Therapy resistance
Dr Miguel Reis Ferreira	Guys and St Thomas NHS Foundation Trust / King's College London	Clinical research	Microbiome	Radiotherapy
Mr David Fisher	University College London	Meta-analysis	Methodology	Survival analysis
Dr Claire Fletcher	Imperial College London	Non-coding RNA	Adipose	Extracellular vesicles
Miss Nuria Mascaro Fortuno	Imperial College London	Clinical trials	Abscopal effect	miRNAs
Dr Alex Freeman	University College London Hospital	PSMA PET	Artificial Intelligence	CTC
Professor Rhian Gabe	Queen Mary University of London	Screening	MRI	PSMA PET
Miss Emily Gill	University of Bristol	Lentiviral transduction	Western blotting	Cell culture

Dr Peter Godolphin	MRC Clinical Trials Unit at UCL	Statistics	Clinical trials	Meta-analysis
Dr Sarah Gosling	Keele University	Early prostate cancer	Cell culture	Analytical techniques
Miss Maria Gouveia	Imperial College London	Genetic engineering	CRISPR	Molecular biology
Mr Struan Gray	The Christie NHS Foundation Trust	Radiomics	Body composition	CT imaging
Dr Harry Green	University of Exeter	Genomics	Data Science	Mathematics
Mr Kyle Greenland	Imperial College London	Tumour microenvironment	Therapeutic resistance	Novel therapeutics
Professor Charlene Greenwood	Keele University	Managing a multidisciplinary team	Materials science	Industrial collaboration
Ms Rosie Gribben	Ulster University	Molecular biology	microRNA biology and gene regulation	Cell biology
Dr Emily Grist	University College London	Biomarkers	Clinical trials	Translational medicine
Dr Nil Grunberg	Imperial College London	Obesity	Extracellular vesicles	Adipocytes
Professor Emma Hall	The Institute of Cancer Research, London	Clinical trial design	Radiotherapy trials	
Mr Tom Harding	University of Bristol	Prostate cancer epidemiology	Electronic health records screening	
Mr Sam Hawkins	Cardiff University	Signalling pathways	Metastatic disease	Molecular biology
Dr Ahmet Hazini	University of Oxford	Immunotherapy	Cancer vaccines	Tumour associated macrophages
Mr Mehmet Hazirci	Imperial College London	Resistance mechanisms	CRISPR Screening	Molecular biology
Dr Susan Heavey	University College London	Spatial multiomics	Explant culture	Fellowship applications
Professor Rakesh Heer	Imperial College London	Prostate cancer biology	Clinical trials	
Miss Jessica Hembrough	Cardiff University	Wnt signalling in vitro	Cell-based assays	Cancer Associated Fibroblasts

Dr James Hindley	King's College London	Nanomedicine	Microfluidics	Tumour microenvironment biochemistry
Mr Kieran Hodson	Cardiff University	Wnt signalling	In vivo metastasis modelling	In vitro functional assays
Dr Kirsty Hodgson	Newcastle University	Glycans	Bone metastases	Sialylation
Dr Isobella Honeyborne	Cardiff University	Extracellular vesicles	Transcriptomics	Serum analyses
Dr Rachel Hurst	Norwich Medical School, University of East Anglia	Bacterial infection associated with aggressive prostate cancer	Clinical trials	Biomarkers to detect aggressive prostate cancer and prognostic tests
Dr Ameera Jailani	University of Sheffield	Drug discovery	High-throughput screening	In vivo models
Dr Jennie Jeyapalan	University of Nottingham	Epigenetics	Transcriptomics	Gene manipulation
Dr Yisheng Ji	Imperial College London	Spatial transcriptomics	Clinical trial management	
Miss Sophie Khan	Ulster University	Genomic medicine	Pharmacogenomics	Pathology
Professor Anne Kiltie	University of Aberdeen	Dietary fibre	Clinical trials	Radiotherapy side effects
Dr Robert Kypta	Imperial College London	Signalling		
Dr Chun Fui Lai	Imperial College London	CDK inhibitors	CRISPR gene editing and molecular biology techniques	
Professor Athene Lane	University of Bristol	Clinical trials	Reported outcome trials	Methodology
Dr Damien Leach	Imperial College London	Stroma	3D-models	Transcriptomics
Mrs Andressa Dias Leao	King's College London	Gut microbiota	Metagenomics	
Dr Jacky Leung	The Institute of Cancer Research, London	Cell biology	Androgen receptor signalling	Redox biology
Dr Mark Linch	University College London	Spatial transcriptomics	Cancer models	Immunotherapy
Dr Emma Lishman-Walker	Newcastle University	Cell signalling	Models	Molecular biology

Dr Taha Lodhi	University of Manchester	Radioresistance	Biomarker development	Translational oncology
Professor Yong-Jie Lu	Barts Cancer Institute, Queen Mary University of London	Circulating biomarkers	Cancer early detection	Host immune response
Ms Shelly Lum	The Institute of Cancer Research, London	Molecular biology	Molecular imaging	Radiochemistry
Mr Ricardo Almeida Magana	University College London	Clinical trials	Surgery	Innovation
Dr Sharmin Malekout	The Royal Marsden NHS Foundation Trust	Whole body MRI	Oncological imaging	Clinical trials
Dr Zoe Maylin	University of British Columbia	PDX models	Novel therapeutics	Mechanistic investigations
Dr Nikhil Mayor	Imperial College London	Prostate cancer screening	Diagnostics	Imaging
Mrs Sarah McCarley	Barts Cancer Institute, Queen Mary University of London	Circulating tumour cells	Biomarkers	Megakaryocytes
Miss Shauna McClelland	Queen's University Belfast	Treatment resistance	Tumour microenvironment	Hypoxia
Professor Karen McCloskey	Queen's University Belfast	Ion channel physiology	Group leader and mentoring	Cellular imaging
Professor Simon McDade	Queen's University Belfast	Genomics	Treatment induced vulnerabilities	Software-tools
Professor Iain McEwan	Institute of Medical Sciences, University of Aberdeen	Androgen receptor	Novel small molecule inhibitors	CRPC
Dr Niamh McKerr	Queen's University Belfast	Molecular biology	Calcium channels	Treatment resistance
Dr Alan McWilliam	University of Manchester	Radiotherapy	Toxicity	Artificial Intelligence
Professor Paula Mendes	University of Birmingham	Glycan detection	Diagnostic assay	Sensors
Professor Ian Mills	University of Oxford	Metabolism	Transcriptomics	Cell signalling
Professor Nigel Mongan	University of Nottingham	Genomics and bioinformatics	Androgen receptor and gene regulation	Pharmacology
Miss Manuella Siaka Monthe	Newcastle University	Flow cytometry	Single-cell sequencing	Mouse models

Mr Sam Morris	Imperial College London	Imaging		
Dr Elisavet Moschopoulou	Queen Mary University of London	Prostate cancer screening	Designing fair recruitment strategies to reduce inequalities	
Dr Debbie Moss	Queen's University Belfast	Radiotherapy	Normal tissue sparing	Molecular biology
Dr Jennifer Munkley	Newcastle University	Glycans	Biomarkers	Commercialisation
Dr Laura Murphy	University College London	Statistics	Cancer trials (STAMPEDE)	Meta-analysis (STOPCAP)
Dr Julia Murray	The Institute of Cancer Research, London	Prostate radiotherapy	Imaging in radiotherapy	Metastasis directed therapy
Miss Hamida Mussa	Imperial College London	miRNAs	Molecular and cellular biology	Explants
Professor Bill Nailon	Edinburgh Cancer Centre	Radiotherapy	Imaging	Machine Learning
Dr Alexander Ng	University College London	Artificial Intelligence	MRI	Clinical trials
Dr Ifeanyichukwu Nwanji	University of Nottingham	Histopathology		
Mr Dami Nwankpele	Imperial College London	Molecular biology	Periprostatic adipose tissue	Science communication
Ms Karen Nyga	Imperial College London	Molecular biology		
Dr Uzoamaka Okoli	University College London	Spatial transcriptomics	Organoids and radiotherapy	
Dr Brian Ortmann	Newcastle University	Molecular biology	Tumour microenvironment	Hypoxia
Dr Simon Pacey	University of Cambridge	Early phase clinical trials	Experimental medicine and window of opportunity trials	
Dr Alec Paschalis	The Institute of Cancer Research, London	Early phase clinical trials	Drug discovery and development	Target identification and validation
Dr Alisha Pati-Alam	University College London	Prostate cancer	Radiorecurrence / radioresistance	Spatial transcriptomics
Mr Rodhan Patke	University of Nottingham	RNA methylation	Immunohistochemistry	Bioinformatics
Dr Helen Pearson	Cardiff University	Preclinical trials	Mouse models	Tissue microarrays

Miss Jess Peng	Newcastle University	Glycans	Immunotherapy	Prognostics
Dr Antoinette Perry	University College Dublin	Epigenetics	Liquid biomarkers	Cannabinoid signalling
Dr Edward Phillips	Imperial College London	Transcriptional inhibitors	CDK12	Clinical trials
Ms Sue Powell	Imperial College London	Molecular biology		
Dr Demi Pritchard	Swansea University	Extracellular vesicles	Patient samples	Glycobiology
Mr Jonathan Pushpa-Rajah	University of Cambridge	Molecular biology	Computational biology (bioinformatics, machine learning)	Surgical oncology
Dr Samantha Quaife	Queen Mary University of London	Cancer screening uptake	Behavioural science	Behaviour change
Dr Conrado Guerrero Quiles	University of Manchester	Omics analysis	In vitro models	Radiotherapy
Dr Masar Radhi	University of Manchester	Molecular biology	Prostate cancer	Radioresistance
Dr Srinivasa Rao	University of Oxford	Spatial genomics and multiomics	Whole slide image analysis (deep learning)	Tumour evolution
Dr Pasquale Rescigno	Newcastle university	Clinical trials		
Dr Anna Richards	Cardiff University	Molecular biology	Fibroblasts	Tissue culture
Dr Gareth Richards	University of Sheffield	Drug development	Pharmacology	GPCRs
Dr Ed Roberts	CRUK Scotland Institute	Immunology	Lymph node	Imaging
Professor Craig Robson	Newcastle University	Preclinical models	Androgen Receptor signalling	Single-cell biology
Dr Hannah Rush	MRC Clinical Trials Unit at UCL	Androgen deprivation therapy	Quality of life	Clinical trials
Dr Ashwin Sachdeva	University of Manchester	Clinical trials	Translational research	Imaging
Ms Melissa Santos	University of Westminster	Molecular biology	Cancer biology	Genetics
Dr Koichi Sasaki	Imperial College London	Immunotherapy	Protein engineering	Cell engineering

Ms Michelle Saull	Queen Mary University of London	Data management	Translational research	
Dr Shaun Scaramuzza	University of Manchester	Molecular biology	DNA damage and repair	Hereditary prostate cancer
Dr Emma Scott	Newcastle University	Glycobiology	Immunology	Myeloid cells
Professor David Sebag-Montefiore	University of Leeds	Clinical trials	Radiotherapy	Predictive biomarkers
Ms Amira Mahmoud Shafik	University of Nottingham	Epitranscriptomics	Pathology	Bioinformatics
Miss Aishwarya Shah	University College London	MRI	Artificial Intelligence	Clinical trial
Dr Amen Shamim	University of Manchester	Multiomics	Transcriptomics	Genomics
Dr Adam Sharp	The Institute of Cancer Research, London	Prostate cancer biology	Drug discovery and development	Prostate cancer medicine
Miss Molly Sharp	Newcastle University	Glycans	Cancer biology	Cell biology
Professor Greg Shaw	University College London	Surgery	Clinical trials	Supporting Afro-Caribbean men with prostate cancer
Dr Jane Shortall	University of Manchester	Radiotherapy	PSA	Outcome prediction
Ms Bipusha Tha Shrestha	University of Leicester	Molecular biology	Genetics	Pathology
Dr Sara Simao	University of Manchester	Health Psychology	Behavioural science	PPIE
Dr Annabelle South	Institute of Clinical Trials and Methodology, UCL	Research communication	Clinical trials	Research impact
Professor John Spencer	University of Sussex	PROTACs	Chemical libraries	Fragment based drug discovery
Professor John Staffurth	Cardiff University	Clinical trials	Radiotherapy	NHS implementation
Dr Sneha Swaroop	University of Bradford	In vitro models	Cancer stem cells and pathways	

Dr Emma Symonds	Imperial College London	Molecular biology	Patient recruitment	In vitro model development
Dr Joe Taylor	The Institute of Cancer Research, London	mRNA translation	Drug discovery	Translational research
Miss Rachel Thompson	University of Nottingham	Epitranscriptomics	Translation	Therapeutics
Professor Jayne Tierney	MRC Clinical Trials Unit at UCL	Treatments for metastatic prostate cancer	Meta-analysis	Surrogate outcomes
Dr Boris Tocco	King's College London	Radiation enteropathy	Microbiome	Machine learning
Dr Nina Tunariu	The Institute of Cancer Research, London	WBMRI	PSMA PET	Trial imaging criteria
Dr Daniel Turnham	University of the West England, Bristol	Cell biology	Preclinical screening	Primary cell culture
Professor Clare Verrill	University of Oxford	Artificial Intelligence	Pathology	Genomics
Mrs Victoria Vickerstaff	Queen Mary University of London	Clinical trials	Statistics	TRANSFORM trial
Professor Fiona Walter	Queen Mary University of London	Primary care	Cancer detection	Diagnostic tests
Dr Ning Wang	University of Leicester	Bone metastasis	Animal models	Metabolism
Mr Qi Wang	CRUK Scotland Institute	Radiobiology	Proteomics	Spatial biology
Professor William Watson	University College Dublin	Biomarkers	Risk Calculators	Tumour microenvironment
Professor David Waugh	Adelaide University	Molecular oncology	Entrepreneurial research	Translational studies
Dr Jason Webber	Swansea University	Extracellular vesicles	Tumour microenvironment	Biomarker development
Professor Catharine West	University of Manchester	Radiotherapy	Transcriptomics	Radiogenomics
Mr Jamie Wills	Newcastle University	Immunology	Mouse models	Glycosylation
Dr Melissa LaBonte Wilson	Queen's University Belfast	Murine models	Radiation and ARTA treatment resistance	Epigenetics

Dr Corinne Woodcock	University of Nottingham	Molecular biology	Epitranscriptomics	Treatment resistance
Dr Zhuolin Yang	University of Edinburgh	Radiomics	Machine learning	Toxicity prediction
Dr Feier Zeng	University of Leicester	Bone metastasis	Inflammation	Molecular biology
Ms Wanting Zeng	The Institute of Cancer Research, London	Molecular biology	AR signalling	mCRPC
Miss Xinwei Zhou	Imperial College London	Micro RNA regulation in prostate cancer	Ex vivo functional studies on prostate cancer biopsies	Molecular mechanisms of cell cycle control
Dr Ralf Zwacka	University of Essex	Mesenchymal stem cells	Apoptosis	Cell therapy

THANK YOU!

We can't wait to see you at **From Ideas to Innovation!**



PROSTATE CANCER UK